Nasus Pharma Ltd. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
NSRX NYSE American 2830 www.nasuspharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Nasus Pharma Ltd.

Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing - Jun 26th, 2026 6:35 am
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th - Jun 23rd, 2026 6:35 am
NSRX: NS002 June KOL Event - Jun 22nd, 2026 6:04 am
Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum - Jun 22nd, 2026 6:00 am
Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003) - Jun 9th, 2026 6:00 am
Nasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of Anaphylaxis - Jun 1st, 2026 6:00 am
NSRX: Initiating Coverage – Sniffing Out a Better Solution - May 22nd, 2026 1:00 am
Nasus Pharma to Participate in Upcoming Investor Conferences - May 1st, 2026 7:14 am
RedChip's Biotech Virtual Investor Conference Replays Now Available - Apr 21st, 2026 1:00 pm
RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms - Apr 7th, 2026 9:00 am
Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update - Mar 25th, 2026 7:00 am
BriefCast Publishes Transcript: Nasus Pharma NS002 Phase 2 Positive Topline Results Webinar Transcript - Mar 19th, 2026 8:06 am
NSRX: NS002 Phase II Topline Results - Mar 16th, 2026 7:17 am
Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold - Mar 16th, 2026 5:30 am
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing - Mar 13th, 2026 6:35 am
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th - Mar 10th, 2026 8:21 am
Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study - Mar 9th, 2026 6:30 am
Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum - Mar 9th, 2026 6:00 am
Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026 - Feb 17th, 2026 6:00 am
Nasus Pharma Announces Closing of $15.0 Million Private Placement - Feb 13th, 2026 6:00 am